The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
LexisNexis
Advertisement
Articles by LexisNexis
Advertisement
Latest Updated Articles
- March 2017: Big Data, Big Opportunity in Life Sciences
Published: March 1st 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
2
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
3
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
4
Carvykti Displays Sustained Remissions in Early Use for Relapsed or Refractory Multiple Myeloma
5
